// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

18,990
Stories Indexed
Live
Feed Status
6
Data Sources
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
ALL STORIES · 18,990 results Live
FDA SAGENT May 11 — 0.00

FDA Approves Unknown Drug — SAGENT PHARMS INC

# FDA Approves Generic Drug Application for Sagent Pharmaceuticals Sagent Pharmaceuticals Inc. received FDA approval for ANDA 203608 on May 11, 2017, expanding its generic drug po…

FDA Novartis May 4 — 0.00

FDA Approves KISQALI FEMARA CO-PACK — Novartis Pharmaceuticals Corporation

Novartis has secured FDA approval for the co-packaged fixed-dose combination of KISQALI and Femara (ribociclib and letrozole), a strategic move aimed at improving medication adhere…

FDA AstraZeneca May 1 — 0.00

FDA Approves IMFINZI — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's IMFINZI (Durvalumab) for Cancer Treatment AstraZeneca Pharmaceuticals LP has received FDA approval for IMFINZI (durvalumab), an intravenous immunother…

FDA RISING Apr 28 — 0.00

FDA Approves Unknown Drug — RISING

# FDA Approves Rising's Generic Drug Application The FDA approved ANDA200542 for Rising Pharmaceuticals on April 28, 2017, expanding the company's generic drug portfolio and posit…

FDA Apotex Apr 28 — 0.00

FDA Approves AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE — Apotex Corp.

On April 28, the FDA approved a generic version of the nasal spray AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE manufactured by Apotex Corp., representing significant market…

FDA Azurity Apr 25 — 0.00

FDA Approves XATMEP — Azurity Pharmaceuticals, Inc.

# FDA Approves Azurity Pharmaceuticals' XATMEP Oral Methotrexate Formulation Azurity Pharmaceuticals has received FDA approval for XATMEP (methotrexate), an oral formulation of th…

FDA Protega Apr 20 — 0.00

FDA Approves ROXYBOND — Protega Pharmaceuticals Inc

Protega Pharmaceuticals Inc. has received FDA approval for Roxycbond (oxycodone hydrochloride), a crucial strategic addition for the company intended to bolster its market portfoli…

FDA Unichem Apr 13 — 0.00

FDA Approves PIROXICAM — Unichem Pharmaceuticals (USA), Inc.

# FDA Approves Piroxicam Generic for Unichem Pharmaceuticals Unichem Pharmaceuticals (USA), Inc. received FDA approval for its generic piroxicam oral formulation, expanding the co…

FDA RISING Apr 7 — 0.00

FDA Approves Unknown Drug — RISING

# FDA Approves Rising Pharmaceuticals' Generic Drug Application Rising Pharmaceuticals has received FDA approval for an abbreviated new drug application (ANDA 207367), expanding i…

FDA RISING Apr 4 — 0.00

FDA Approves Unknown Drug — RISING

# FDA Approves Rising Pharmaceuticals' Generic Drug Application Rising Pharmaceuticals has received FDA approval for ANDA200217, expanding its generic drug portfolio and positioni…

FDA Genentech, Mar 28 — 0.00

FDA Approves OCREVUS — Genentech, Inc.

# FDA Approves Genentech's OCREVUS for Multiple Sclerosis Treatment Genentech announced FDA approval of OCREVUS (ocrelizumab), an intravenous monoclonal antibody therapy, position…

FDA Camber Mar 22 — 0.00

FDA Approves OXYCODONE AND ACETAMINOPHEN — Camber Pharmaceuticals, Inc.

Camber Pharmaceuticals gained FDA approval for its ANDA207419 formulation of oxycodone and acetaminophen tablets, granting the company the rights to supply a lower-cost alternative…

FDA Aurobindo Mar 22 — 0.00

FDA Approves TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN — Aurobindo Pharma Limited

The FDA has granted approval to Aurobindo Pharma Limited for its generic Tramadol Hydrochloride oral product, marking a new competitive entry into the opioid analgesic market. This…

FDA Accord Mar 21 — 0.00

FDA Approves OXALIPLATIN — Accord Healthcare Inc.

# FDA Approves Generic Oxaliplatin from Accord Healthcare Inc. Accord Healthcare Inc. received FDA approval for a generic version of oxaliplatin, an intravenous chemotherapy drug,…

FDA TEVA Mar 10 — 0.00

FDA Approves Unknown Drug — TEVA PHARMS USA

TEVA PHARMS USA reported the approval of its Abbreviated New Drug Application (ANDA 205807) on March 10, 2017, a milestone that positions the company to enter the generic market fo…

FDA AMNEAL Feb 28 — 0.00

FDA Approves Unknown Drug — AMNEAL PHARMS

On February 28, 2017, Amneal Pharmaceuticals received approval for ANDA 204741, a development that positions the company in significant market trial related to the specified substa…

FDA RISING Feb 28 — 0.00

FDA Approves Unknown Drug — RISING

Rising has received final FDA approval for its Abbreviated New Drug Application (ANDA #204043), positioning itself for entry into the market once the original product patent expire…

FDA ASTRAZENECA Feb 27 — 0.00

FDA Approves Unknown Drug — ASTRAZENECA AB

# FDA Approves AstraZeneca Drug, Expanding Treatment Options in Key Therapeutic Area The U.S. Food and Drug Administration has approved AstraZeneca AB's new drug application (NDA2…

FDA Lupin Feb 24 — 0.00

FDA Approves OXYCODONE AND ACETAMINOPHEN — Lupin Pharmaceuticals,Inc.

**FDA Approves ANDA for Lupin’s Oxycodone and Acetaminophen Combination Product** On February 24, 2017, the FDA approved Lupin Pharmaceuticals' Abbreviated New Drug Application fo…

FDA Bausch Feb 15 — 0.00

FDA Approves SILIQ — Bausch Health US LLC

Bausch Health US LLC secured FDA approval for the subcutaneous formulation of Brodalumab under the brand SILIQ, a move expected to significantly diversify its biologic portfolio an…